A special meeting of stockholders was held virtually via live webcast on February 26, 2026. Stockholders voted in favor of adopting the Agreement and Plan of Merger with Novartis AG and the Separation and Distribution Agreement for Bryce Therapeutics, Inc. (now Atrium Therapeutics, Inc.). As of the record date, January 29, 2026, 154,740,172 shares of common stock were eligible to be voted. At the meeting, 123,715,570 shares, or approximately 79.95% of all outstanding shares, were present either in person or by proxy. The Transactions Proposal was approved with 123,351,048 votes For, 8,090 Against, and 60,331 Abstentions. The Non-Binding Merger-Related Compensation Proposal was also approved with 101,383,553 votes For, 21,654,186 Against, and 381,730 Abstentions. The Adjournment Proposal was not voted upon as there were sufficient votes to approve the Transactions Proposal. The approval of the Transactions Proposal satisfies the stockholder vote condition required for the consummation of the transactions.